Your browser doesn't support javascript.
loading
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer.
Xiang, Hong; Chan, Abigael G; Ahene, Ago; Bellovin, David I; Deng, Rong; Hsu, Amy W; Jeffry, Ursula; Palencia, Servando; Powers, Janine; Zanghi, James; Collins, Helen.
  • Xiang H; Five Prime Therapeutics, Inc, South San Francisco, California.
  • Chan AG; Clinical Pharmacology, Modeling and Simulation, Amgen Inc, Thousand Oaks, California.
  • Ahene A; Five Prime Therapeutics, Inc, South San Francisco, California.
  • Bellovin DI; Global Project Management, Zai Lab (US) LLC, Menlo Park, California.
  • Deng R; Five Prime Therapeutics, Inc, South San Francisco, California.
  • Hsu AW; Bioanalytic Sciences, Amgen Inc, South San Francisco, California.
  • Jeffry U; Five Prime Therapeutics, Inc, South San Francisco, California.
  • Palencia S; Bioanalytic Sciences, Amgen Inc, South San Francisco, California.
  • Powers J; R&D Q-Pharm Consulting LLC, Pleasanton.
  • Zanghi J; Five Prime Therapeutics, Inc, South San Francisco, California.
  • Collins H; Research, Merck & Co., Inc, South San Francisco, California.
MAbs ; 13(1): 1981202, 2021.
Article en En | MEDLINE | ID: mdl-34719330
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2021 Tipo del documento: Article